Your email has been successfully added to our mailing list.

×
0 0 0 -1.42793958151146E-16 0.109324758842444 -0.0321543408360129 -0.0257234726688103 -0.0144694533762059
Stock impact report

Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma

ZIOPHARM Oncology Inc (ZIOP) 
Last ziopharm oncology inc earnings: 3/2 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ziopharm.com
Company Research Source: GlobeNewswire
BOSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending Ad-RTS-hIL-12 plus veledimex (Controlled IL-12) for designation as an orphan medicinal product for the treatment of glioma. “Malignant glioma is an aggressive and life-threatening cancer with few treatment options,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. “We are pleased to receive a positive opinion from EMA COMP for orphan drug designation, as this represents another important milestone for our clinical program to treat recurrent glioblastoma multiforme.” Orphan Medicinal Product designation by the European Commission provides certain regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more t Show less Read more
Impact Snapshot
Event Time:
ZIOP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ZIOP alerts
Opt-in for
ZIOP alerts

from News Quantified
Opt-in for
ZIOP alerts

from News Quantified